Tracy Warren has over fifteen years of experience as an entrepreneur and early stage investor in life science and energy companies, with an affinity for institutional-based technology commercialization. Serves on boards of for-profit and non-profit entities across sectors, with primary interest in health and life sciences.
As an investor, Tracy led investments in NuPathe, which completed its IPO in 2010 and was subsequently acquired by Teva Pharmaceuticals for over $140 million. She also served as Chairman of BioNano Genomics and on the Board of Micro Interventional Devices.
In October, 2014, to leverage over a decade of technology commercialization expertise, Tracy launched FedIMPACT, LLC, a joint venture with IP Group, focused on creating technology spin-out companies from the U.S. Department of Energy national laboratories.
As an entrepreneur, Ms. Warren co-founded NellOne Therapeutics, a soft-tissue regenerative medicine company based on the NELL1 gene based on work initiated at Oak Ridge National Laboratory by her co-founder, Dr. Cymbeline Culiat.
Having spent over a decade commercializing technologies from nation’s leading institutions, Tracy serves on the Boards of Children’s Research Institute (CRI) at Children’s National Medical Center (Washington, DC) and Clemson University Research Foundation, and is a member of the Business Advisory Council to the Sheikh Zayed Institute for Pediatric Surgical Innovation. In addition to her investment activities, she also provides early-stage leadership to other businesses, currently serving as an adviser and mentor to life science female entrepreneurs through Springboard Enterprises and co-chairs the Portfolia Active Aging Fund.
MEDIA ABOUT TRACY WARREN